Results 131 to 140 of about 1,908,445 (275)
Supplement to Spons ̓dictionary of engineering, civil, mechanical, military, and naval
, 1879 Edward Spon +3 more
openalex +2 more sources
TRPM8 levels determine tumor vulnerability to channel agonists
Molecular Oncology, EarlyView.TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo +18 more
wiley +1 more source
Science and Civilization in China: Volume 4, Part 2: Mechanical Engineering [PDF]
, 1966 Donald Cardwell
openalex +1 more source
Molecular Oncology, EarlyView.The pan‐HDAC inhibitor belinostat increases the expression of the pro‐apoptotic proteins Bim, Puma, and Noxa and induces apoptosis in ovarian cancer cell lines and patient‐derived tumor organoids when used at high concentrations. Moreover, inhibiting the anti‐apoptotic proteins Bcl‐xL or Mcl‐1 sensitizes these preclinical models to the cytotoxic effect
Cécilia Thomine +10 more
wiley +1 more source
Molecular Oncology, EarlyView.The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song +11 more
wiley +1 more source
Heliyon, 2019 Background: The Hip joint is the primary joint which gives stability to the human body. The wear and tear associated with age and other factors, require these joints to be replaced by implants using hip arthroplasty surgeries. Cobalt chromium alloy (CoCr)
Chethan K.N. +4 more
doaj
Functions and Training of the Mechanical Engineer
Proceedings of the Institution of Mechanical Engineers, 1922 n ...
openaire +3 more sources
Molecular Oncology, EarlyView.In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton +17 more
wiley +1 more source